Replies to post #104189 on NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

"The median OS of the group of 51 Information Arm patients as a whole is 18.3 months. About 30% of the patients (15 of the 51) lived beyond 2 years, and most of these patients (12 of the 15) remain alive. "

excerpt from news release, linked below: (so not 14 months)

No. It is very clear that it is 14 months. Look at the Info Arm abstract.

The numbers reported: "Median overall survival in this cohort from initial GBM diagnosis".....

The Info Arm Abstract only focused on the ePD patients (well, also the 8 rGBM patients from the P1 study where they calculated the mean instead of the median).

The Info Arm poster focused not just on the ePD, but the entire 51 patients in the Info Arm. The survival numbers in the PR and Poster are from initial diagnosis.

So, if you want to compare it to the ICT-107 cohort, since ICT107 randomized 4 months later, you need to subtract the 4 months.